Advertisement
Advertisement

KNSA

KNSA logo

Kiniksa Pharmaceuticals International, plc Class A Ordinary Shares

77.09
USD
Sponsored
-0.82
-1.05%
Sep 08, 15:59 UTC -4
Closed
exchange

Pre-Market

76.75

-0.34
-0.44%

KNSA Earnings Reports

Positive Surprise Ratio

KNSA beat 19 of 33 last estimates.

58%

Next Report

Date of Next Report
Oct 26, 2026
Estimate for Q3 26 (Revenue/ EPS)
$264.79M
/
$0.37
Implied change from Q2 26 (Revenue/ EPS)
+8.70%
/
+23.33%
Implied change from Q3 25 (Revenue/ EPS)
+46.41%
/
+60.87%

Kiniksa Pharmaceuticals International, plc Class A Ordinary Shares earnings per share and revenue

On Jul 28, 2026, KNSA reported earnings of 0.30 USD per share (EPS) for Q2 26, missing the estimate of 0.30 USD, resulting in a -1.54% surprise. Revenue reached 243.60 million, compared to an expected 229.97 million, with a 5.93% difference. The market reacted with a +25.03% price change (close before vs. close after earnings).
Looking ahead to Q3 26, 6 analysts forecast an EPS of 0.37 USD, with revenue projected to reach 264.79 million USD, implying an increase of 23.33% EPS, and increase of 8.70% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

logo
Clinuvel Pharmaceuticals Limited - ADR
Report Date
Aug 27, 2026 For Q4 26
Estimate
$0.50
Actual
-
Surprise
-
FAQ
For Q2 2026, Kiniksa Pharmaceuticals International, plc Class A Ordinary Shares reported EPS of $0.30, missing estimates by -1.54%, and revenue of $243.60M, 5.93% above expectations.
The stock price moved up 25.03%, changed from $63.53 before the earnings release to $79.44 the day after.
The next earning report is scheduled for Oct 26, 2026.
Based on 6 analysts, Kiniksa Pharmaceuticals International, plc Class A Ordinary Shares is expected to report EPS of $0.37 and revenue of $264.79M for Q3 2026.
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement